Call UsCall Us:- +8618060810639

LGD-4033 (Anablicum)

LGD-4033 (Anablicum)

Product Details:

8500 USD ($)/Kilograms
X

LGD-4033 (Anablicum) Price And Quantity

  • 20 Ton
  • 8500 USD ($)/Kilograms
  • 6500.00 - 13000.00 USD ($)/Kilograms

LGD-4033 (Anablicum) Trade Information

  • Shanghai China
  • Telegraphic Transfer (T/T)
  • 600 Ton Per Month
  • 3 Days
  • Within a certain price range free samples are available
  • 1kg/bottle
  • Australia North America Western Europe Central America Africa Eastern Europe Middle East South America Asia
  • All India
  • COA

Product Description

Product Name:LGD-4033(Anablicum)

Synonym:LGD-4033;Anablicum;1165910-22-4;Lingandrol;CS-2033;D-4033;GD-4033;VK5211;Ligandrol-d3

Molecular Formula:C14H12F6N2O

Formula Weight:338.25

CAS No.:1165910-22-4


Description:Anablicum (LGD-4033) is a selective androgen receptor modulator (SARM), discovered by Ligand Pharmaceuticals Inc and perfected by SARMS1. LGD-4033 binds to the androgen receptor of muscle and bone selectively, exhibiting similar effects as testosterone, with only partial agonist activity on the prostate. It was developed as a way to treat diseases or conditions associated with muscle and bone deterioration. The advantage a SARM like LGD has over testosterone is the difference in activity it has on the body outside of muscle and bone.

Anabolicum (LGD-4033) is unarguably the strongest SARM on the market today as far as anabolic power. It adds extra muscle building power to a cutting cycle, strength and size to a bulking cycle, and resilience for the endurance athlete. Used by itself or stacked with one or more other compounds, LGD demands recognition in the world of health, fitness, and bodybuilding.

How it works

LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033 has recently completed a Phase I Multiple Ascending Dose study in healthy volunteers. This randomized, double-blind, placebo-controlled Phase I study established the safety and tolerability up to doses of 22 mg per day.

Enter Buying Requirement Details
Email Id
Mobile number

Other Products in 'Pharmaceutical Material' category